[ad_1]
Cancers of the colon and rectum are often grouped together because they have many common features. In the United States, the colorectal cancer rate is increasing in generation Y The American Cancer Society (ACS) estimates that there will be about 97,220 new cases of colon cancer and about 43,030 new cases of rectal cancer registered in the United States in 2018. increased risk of colorectal cancer, in May 2018, ACS updated its guidelines for colorectal cancer screening and recommended to start screening for colorectal cancer at the same time. age 45 rather than 50 years old.
Market for Colon and Rectal Cancer Drugs – Drivers
The increase in the incidence and prevalence of colon and rectal cancer worldwide and colorectal cancer research and development studies are expected to stimulate growth in the colon cancer and colorectal cancer market. rectum in the near future. For example, according to the February 2018 data from the American Cancer Society (ACS), colorectal cancer is the third most frequently diagnosed cancer among men and women in the United States.
Get HOLISTIC Request a sample copy of this Activity Report:
https://www.coherentmarketinsights.com/insight/request-sample/2019
In addition, according to the Center for Disease Control and Prevention (CDC), approximately 139,992 people in the United States have been diagnosed with colorectal cancer, including 73,396 men and 66,596 women. Of these, approximately 51,651 people in the United States died from colorectal cancer, 27,134 men and 24,517 women. In addition, according to 2012 data from the World Health Organization (WHO), colorectal cancer is the third most important cancer in men (746,000 cases, 10.0% of the total) and the second in importance for women (614 000 cases, 9.2% in total) worldwide in 2012. In addition, about 55% of these cases occurred in developed regions.
An increasing number of research and development (R & D) studies by public and private health organizations are also fueling the growth of the colon and rectal cancer market. For example, the American Cancer Society (ACS) spent 54 million US dollars for cancer research on the colon and rectum, involving 92 research grants, until March 2018.
Drug Market for Colon and Rectal Cancer – Constraints
The lack of development of neoadjuvant / adjuvant agents in the pipeline for the treatment of high-risk colorectal cancer has resulted in slower growth of the cancer drug market for colon and rectal cancer. For example, according to data published in the National Biotechnology Information Center (NCBI) in April 2016, clinical trials of adjuvant, neoadjuvant and perioperative systemic chemotherapy for the treatment of colorectal liver metastases are insufficient. These offer a lucrative opportunity for key players to develop a new treatment using neoadjuvant agents for resected patients.
In addition, inappropriate reimbursement policies for the treatment of colorectal cancer in some countries hinder the growth of the global market for colon and rectal cancer drugs. For example, according to a comparative study published at the ASCO 2018 meeting of the American Society (ASCO), the cost of treatment for metastatic colorectal cancer in western Washington (United States ) is higher than that of British Columbia (BC) in Canada. significant difference in the result.
Download the brochure in PDF format: https://www.coherentmarketinsights.com/insight/request-pdf/2019
Market for Colon and Rectal Cancer Drugs – Regional Analysis
On a regional basis, the global market for cancer drugs for the colon and rectum is segmented between North America, Latin America, Europe, the Middle East, the United States, and the United States. 39, Asia-Pacific and Africa. North America occupies a dominant position in the market for drugs for colon and rectal cancer, followed by Europe. This is due to the increasing incidence of colorectal cancer in these areas. According to the World Cancer Research Fund International, the Republic of Korea had the highest colorectal cancer rate in 2012, followed by Slovakia and Hungary. In addition, in recent years, many cases of colorectal cancer have been reported in Oceania and Europe, while incidence rates are lowest in Africa and Asia.
Market for Colon and Rectal Cancer Drugs – Competitive Analysis
Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited and Sanofi SA Sorrento Therapeutics and Takeda Pharmaceutical Company Ltd. The main market players are involved in research and development activities aimed at conducting clinical trials and obtaining regulatory authorizations. For example, in March 2018, Daiichi Sankyo initiated a Phase II study on DS-8201 in patients with advanced colorectal cancer expressing HER2. Currently, there is no HER2-targeted treatment approved for patients with colorectal cancer expressing HER2. The launch of a HER2 phase clinical study by Daiichi Sankyo on the treatment of colorectal cancer will help improve outcomes in patients with colorectal cancer. In March 2018, the FDA approved the injection of Opdivo (Nivolumab) from Bristol-Myers Squibb, which is administered intravenously for the treatment of adult and pediatric patients (aged 12 years and older) suffering from alcohol. a high microsatellite instability deficit (MSI-H) or metastatic colorectal cancer.
Purchase a copy of the report @https: //www.coherentmarketinsights.com/insight/buy-now/2019
About us:
Coherent Market Insights is a leading market research and advisory firm offering ready-made underwriting research reports, customized market research, consulting and competitive badysis through a variety of industry trend recommendations. emerging markets, technologies and opportunities in potential absolute dollars.
Source link
